Join Aura Biosciences (#AURA) for a virtual ocular oncology investor event on Sep. 12 at 8am ET featuring Dr. Ivana Kim, MD (Mass Eye and Ear) and Dr. Prithvi Mruthyunjaya, MD, MHS (Stanford University Byers Eye Institute) to discuss the Phase 2 end of study data evaluating suprachoroidal administration of bel-sar for the first-line treatment of patients with small choroidal melanoma and indeterminate lesions. Register here: https://bit.ly/3XoQbQi
LifeSci Advisors, LLC
Finanzdienstleistungen
New York, New York 15,073 followers
Accelerating Innovations In Life Science.
Über uns
LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences field with a comprehensive solution to investor communications and outreach. Our services are designed to increase our clients’ visibility within the investment community and to educate investors about the opportunity. We strive to effectively communicate each clients’ unique value proposition, building momentum for the investment. We begin with deep due diligence as we partner with each client to gain an unparalleled level of understanding of their business and the opportunities they are addressing. This in-depth knowledge allows us to be able to provide each client partner with thoughtful recommendations related to corporate communications, investor outreach, and capital markets planning. Our strategies and actions are specifically tailored to help each client achieve their investor relations goals.
- Website
-
http://www.lifesciadvisors.com
External link for LifeSci Advisors, LLC
- Industrie
- Finanzdienstleistungen
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- New York, New York
- Typ
- In Privatbesitz
- Gegründet
- 2009
- Spezialitäten
- Investor Relations
Standorte
-
Primäre
250 W 55th St
#3401
New York, New York 10019, US
Employees at LifeSci Advisors, LLC
Aktualisierungen
-
Join ArriVent Biopharma (#AVBP) for a virtual KOL event on Monday, Sep. 9 at 4:30 pm ET featuring Xiuning Le, MD, PhD (The University of Texas MD Anderson Cancer Center) to discuss the unmet need and current treatment landscape for non-small cell lung cancer (NSCLC) EGFR PACC mutations. Register here: https://bit.ly/4cJmPjN
-
-
Join Reviva Pharmaceuticals (#RVPH) for a virtual KOL event on Sep. 4 at 2pm ET, featuring Brian Kirkpatrick, MD (University of Arkansas for Medical Sciences) and Mark Opler, PhD, MPH (WCG Inc., PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia, and application of speech latency as an objective vocal biomarker in schizophrenia clinical trials for evaluation of negative symptoms. Register here: https://bit.ly/4cznhB3
-
-
Join us next Wednesday, August 14th at 12pm ET for the latest in our exclusive webinar series, “Lunch with LifeSci featuring Vera Therapeutics, Inc." where we will interview Dr. Marshall Fordyce, Founder and CEO, and Sean Grant CFO. Register here: https://bit.ly/3SH8FbP
-
-
Join Arrowhead Pharmaceuticals (#ARWR) for Part IV of its Summer Series of R&D webinars on Wed. August 14 at 2PM ET featuring Prof. Carel le Roux, Chair of Metabolic Medicine at University College Dublin. Arrowhead management will provide updates on two preclinical programs addressing obesity and metabolic diseases. Register here: https://bit.ly/3WEy6gI
-
-
Join Gritstone bio (#GRTS) for a virtual KOL event on Friday, Aug. 2 at 9am ET featuring J. Randolph Hecht, MD, (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) who will discuss the unmet need and current treatment landscape for patients with metastatic microsatellite stable colorectal cancer (MSS-CRC). Register here: https://bit.ly/4bXHSPa
-
-
TOMORROW! Join Skye Bioscience Inc. (#SKYE) for a virtual KOL Event on Wed. July 24 at 9am ET featuring Louis J. Aronne, MD, FACP (Weill Cornell Medicine), Marcus DaSilva Goncalves, MD, PhD (NYU Langone Health), Lee M. Kaplan, MD, PhD (Geisel School of Medicine at Dartmouth), and Beverly Tchang, MD (Weill Cornell Medicine), who will discuss the current treatment landscape for obesity, including the role of peripheral CB1 inhibition as a differentiated mechanism. Register: https://bit.ly/3YbdJJ6
-
-
Join Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) for a virtual KOL event on Mon. July 29 at 8:30am ET featuring a leading dermatology expert to discuss the unmet need and current treatment landscape for patients with mild to moderate atopic dermatitis (AD). Register here: https://bit.ly/3zUfUGZ
-
-
Join Faraday Pharmaceuticals, Inc. for a KOL webinar on Tues. July 30 at 11am ET with Dr. Cheerag Shirodaria (Oxford University Hospitals), Dr. Marc Bonaca (University of Colorado Anschutz), and Dr. Antonio Gutierrez (Duke University Hospital and Durham VA Medical Center), who will discuss the unmet need and current treatment landscape in preventing ischemia-reperfusion injury and highlight the effects of STEMI on heart failure and other patient outcomes. Register here: https://bit.ly/4eXHjro
-
-
Join DiaMedica Therapeutics Inc. (#DMAC) for a virtual KOL event on Mon. July 29 at 10am ET featuring Prof. Catherine Cluver, MD, PhD (Stellenbosch University), Prof. Stephen Tong, MD, PhD (The University of Melbourne), and Prof. Susan Walker, MD, PhD (The University of Melbourne) who will discuss the unmet need and current treatment landscape for preeclampsia (PE), a life-threatening pregnancy associated vascular disorder with no approved therapeutics. Register here: https://bit.ly/4cZir0A
-